CLOVER HEALTH INVESTMENTS, CORP. /DE
Congressional Trades
No congressional trades in CLOV on record.
Whale Activity
- Increased77
- New38
- Held58
- Decreased45
- Closed32
- No prior filing11
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 36.5M | $157.4M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 18.4M | $79.2M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 11.1M | $47.9M | increased |
| STATE STREET CORP | 10.7M | $46.1M | increased |
| Nuveen, LLC | 7.8M | $33.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.6M | $32.7M | increased |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 5.9M | $25.3M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 4.6M | $19.6M | increased |
| D. E. Shaw & Co., Inc. | 4.4M | $18.9M | increased |
| NORTHERN TRUST CORP | 3.8M | $16.3M | increased |
| DIMENSIONAL FUND ADVISORS LP | 3.4M | $14.5M | increased |
| VANGUARD FIDUCIARY TRUST CO | 3.1M | $13.3M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| THORNTON JOSEPH CLAYChief Financial Officer | Sale | −22.1K | $4.97 | $110K | Nov 16, 2026 | Form 4 ↗ |
| Soares KarenChief Legal Officer | Sale | −19.3K | $4.66 | $90K | Oct 20, 2026 | Form 4 ↗ |
| Reynoso Jamie L.CEO, Medicare Advantage | Sale | −4,066 | $4.41 | $18K | Oct 19, 2026 | Form 4 ↗ |
| Toy AndrewChief Executive Officer · Director | Sale | −62.2K | $4.68 | $291K | Oct 15, 2026 | Form 4 ↗ |
| Soares KarenChief Legal Officer | Sale | −14.7K | $4.68 | $69K | Oct 15, 2026 | Form 4 ↗ |
| THORNTON JOSEPH CLAYInterim CFO | Sale | −4,591 | $4.68 | $21K | Oct 15, 2026 | Form 4 ↗ |
| Wai ConradCEO, Counterpart Health | Sale | −23.6K | $4.68 | $111K | Oct 15, 2026 | Form 4 ↗ |
| Reynoso Jamie L.CEO, Medicare Advantage | Sale | −18.3K | $4.68 | $86K | Oct 15, 2026 | Form 4 ↗ |
| Reynoso Jamie L.CEO, Medicare Advantage | Sale | −2,006 | $4.63 | $9K | Oct 7, 2026 | Form 4 ↗ |
| Reynoso Jamie L.CEO, Medicare Advantage | Sale | −8,750 | $4.42 | $39K | Oct 5, 2026 | Form 4 ↗ |
| Toy AndrewChief Executive Officer · Director | Sale | −318.8K | $4.19 | $1.3M | Oct 1, 2026 | Form 4 ↗ |
| Reynoso Jamie L.CEO, Medicare Advantage | Sale | −1,921 | $4.56 | $9K | Sep 17, 2026 | Form 4 ↗ |
| OLDAKOWSKI JOSEPH FRANKVP OF FINANCE AND CONTROLLER | Sale | −3,170 | $4.64 | $15K | Sep 16, 2026 | Form 4 ↗ |
| Wai ConradCEO, Counterpart Health | Sale | −300.0K | $4.72 | $1.4M | Sep 15, 2026 | Form 4 ↗ |
| Soares KarenChief Legal Officer | Sale | −6,846 | $4.78 | $33K | Sep 15, 2026 | Form 4 ↗ |
| Reynoso Jamie L.CEO, Medicare Advantage | Sale | −9,273 | $4.78 | $44K | Sep 15, 2026 | Form 4 ↗ |
| OLDAKOWSKI JOSEPH FRANKVP OF FINANCE AND CONTROLLER | Sale | −20.0K | $5.16 | $103K | Sep 14, 2026 | Form 4 ↗ |
| THORNTON JOSEPH CLAYInterim CFO | Sale | −17.8K | $4.39 | $78K | Aug 17, 2026 | Form 4 ↗ |
| Soares KarenChief Legal Officer | Grant / award | +108.7K | $0.00 | $0 | Aug 12, 2026 | Form 4 ↗ |
| THORNTON JOSEPH CLAYInterim CFO | Grant / award | +54.3K | $0.00 | $0 | Aug 12, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 13.0M | $68.0M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 10.8M | $56.6M | 0.07% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.6M | $24.3M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 3.9M | $20.4M | 0.13% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 4.6M | $19.2M | 0.06% | Jul 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 2.4M | $10.0M | 0.06% | Aug 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account College Retirement Equities Fund | 1.8M | $9.7M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 2.0M | $8.2M | 0.02% | Aug 31, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 1.9M | $8.0M | 0.04% | Aug 31, 2026 |
| Nuveen Quant Small Cap Equity Fund TIAA-CREF Funds | 1.8M | $7.4M | 0.18% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list CLOV's shares (CUSIP 18914F103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
No lobbying filings found naming CLOVER HEALTH INVESTMENTS, CORP. /DE as the client.
Government Contracts
No federal contract awards found for CLOVER HEALTH INVESTMENTS, CORP. /DE.
U.S. Patents
No USPTO patent applications found for CLOVER HEALTH INVESTMENTS, CORP. /DE.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.92B | $1.37B | $1.26B | $1.10B | $1.47B |
| Operating income | -$85.5M | -$45.7M | -$205.3M | -$286.7M | -$637.0M |
| Net income | -$85.5M | -$43.0M | -$213.4M | -$339.6M | -$587.8M |
| Diluted EPS | n/a | n/a | -$0.44 | -$0.71 | -$1.42 |
| Operating cash flow | -$66.9M | $34.8M | -$144.7M | -$203.9M | -$282.3M |
| Cash and equivalents | $78.3M | $194.5M | $122.9M | $103.8M | $300.0M |
| Total assets | $541.0M | $580.7M | $570.7M | $808.6M | $950.8M |
| Total liabilities | $232.3M | $239.6M | $284.3M | $451.7M | $410.8M |
| Shareholders' equity | n/a | n/a | n/a | $347.7M | $535.4M |
As CLOVER HEALTH INVESTMENTS, CORP. /DE tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 27, 2026 ↗
Stock Splits
No stock splits in CLOV's price history.
Material Events (8-K)
- 8-K · Items 7.01, 9.01Reg FD disclosureNov 16, 2026
EDGAR ↗ - 8-K · Items 2.02, 5.02, 9.01Results of operations · Officer / director changeNov 4, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureOct 9, 2026
EDGAR ↗ - 8-K/A · Items 5.02, 9.01Officer / director changeSep 25, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeSep 24, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureAug 20, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJul 17, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJun 18, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeJun 16, 2026
EDGAR ↗
